glucose, (beta-d)-isomer has been researched along with Fasting Hypoglycemia in 128 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.56) | 18.7374 |
| 1990's | 1 (0.78) | 18.2507 |
| 2000's | 4 (3.13) | 29.6817 |
| 2010's | 103 (80.47) | 24.3611 |
| 2020's | 18 (14.06) | 2.80 |
| Authors | Studies |
|---|---|
| GONZALEZ, LL; SUMMERS, WA | 1 |
| Dinarello, CA; Fantuzzi, G | 1 |
| Martin, H; Miller, V; Shands, JW | 1 |
| Boeder, SC; Giovannetti, ER; Gregory, JM; Pettus, JH | 1 |
| Seki, H; Watanabe, H; Yorozu, T | 1 |
| Isganaitis, E; Karlsson, C; Laffel, LM; Norjavaara, E; Ratnayake, J; Shehadeh, N; Tamborlane, WV; Van Name, M | 1 |
| Dong, L; Li, H; Li, Y; Lin, D; Lou, P; Ma, L; Wang, K; Xu, L; Zang, D | 1 |
| Bally, L; Dalla Man, C; Emara, AFA; Facchinetti, A; Ferreira, A; Herzig, D; Melmer, A; Nakas, CT; Vogt, AP | 1 |
| Aamir, AH; Ahmed, I; Asghar, A; Ghaffar, T; Ishtiaq, O; Khan, S; Kumar, S; Masood, F; Raja, UY; Randhawa, FA; Raza, A; Rehman, T; Sherin, A; Wahab, MU | 1 |
| Dionisi-Vici, C; Maiorana, A; Tagliaferri, F | 1 |
| Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Mattheus, M; Vedin, O; Wanner, C; Zinman, B | 1 |
| Chilton, R; Sheikh, O; Solis-Herrera, C | 1 |
| Ali, SN; Dang-Tan, T; Ericsson, Å; Hansen, BB; Hunt, B; Kallenbach, K; Malkin, SJP; Valentine, WJ | 1 |
| Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I | 1 |
| Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA | 1 |
| Almdal, TP; Bagge Hansen, K; Holm Schultz, H; Klarskov, CK; Lommer Kristensen, P; Møller Christensen, T; Pedersen-Bjergaard, U; Persson, F; Snorgaard, O | 1 |
| Heilmann, C; Taniguchi, A; Watada, H; Yamamoto, F; Yamauchi, T; Yarush, L; Yasui, A | 1 |
| Ahmed, A; Choi, J; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Sjöström, CD | 1 |
| Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
| Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Haberbosch, L; Spranger, J | 1 |
| de Galan, BE; Tack, CJ; van Meijel, LA | 1 |
| Lingvay, I | 1 |
| Maltezos, E; Pafili, K; Papanas, N | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Birkeland, KI; Bodegard, J; Carstensen, B; Eriksson, JW; Fenici, P; Gulseth, HL; Jørgensen, ME; Nathanson, D; Norhammar, A; Nyström, T; Persson, F; Thuresson, M | 1 |
| Takeishi, S; Takekoshi, S; Tsuboi, H | 1 |
| Chen, L; Tian, D; Wang, L; Xia, P; Xu, L; Zhao, Y; Zheng, H | 1 |
| Bailey, CJ; Jabbour, S; Karup, C; Langkilde, AM; Scheen, A; Seufert, J | 1 |
| Kim, JH; Li, Y; Ma, J; Ptaszynska, A; Yang, W; Zhao, J; Zhou, Z | 1 |
| Brandjes, DPM; Gerards, MC; Gerdes, VEA; Hageman, IMG; Hoekstra, JBL; Kross, M; Patberg, KW; Potter van Loon, BJ; Snijders, D; Venema, GE; Vriesendorp, TM | 1 |
| Matsuba, I; Matsuba, R; Nagai, Y; Shimokawa, M; Tanaka, Y | 1 |
| Gunji, R; Kaku, K; Senda, M; Tamura, M; Terauchi, Y | 1 |
| Bell, KF; Chakravarty, A; Dhankhar, P; Rastogi, M | 1 |
| Chen, H; Del Prato, S; Garcia-Sanchez, R; Hansen, L; Iqbal, N; Johnsson, E; Mathieu, C; Rosenstock, J | 1 |
| George, J; Hanafusa, T; Lee, G; Marquard, J; Sarashina, A; Shiki, K; Shimada, A; Soleymanlou, N; Taneda, Y; Yasui, A | 1 |
| Akturk, HK; Garg, SK; Rewers, A | 1 |
| DeFronzo, RA; Kohler, S; Lee, C | 1 |
| Andersen, KR; Ridderstråle, M; Rosenstock, J; Salsali, A; Woerle, HJ | 1 |
| Scheen, AJ | 1 |
| Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL | 1 |
| Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J | 1 |
| Davis, SN; Hedrington, MS | 2 |
| Adam, J; Ashcroft, FM; Asterholm, IW; Benrick, A; Briant, LJB; Chibalina, MV; Gribble, FM; Hamilton, A; Hastoy, B; Knudsen, JG; Ramracheya, R; Reimann, F; Rorsman, NJG; Rorsman, P; Salehi, A; Spiliotis, II; Tarasov, A; Vergari, E; Wu, Y; Zhang, Q | 1 |
| Garg, SK; Giordano, D | 1 |
| Aharon-Hananel, G; Raz, I | 1 |
| Boeder, S; Edelman, SV | 1 |
| García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J | 1 |
| Dhillon, S | 1 |
| Davis, SN; Lamos, EM; Younk, LM | 1 |
| Bloomgarden, Z | 1 |
| Parikh, S; Rohwedder, K; Sugg, J; Wilding, JP; Woo, V | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Ling, Y; Xu, W; Yang, X; Yang, Y; Zhao, W; Zhao, Y | 1 |
| Barnett, AH; Goring, S; Hawkins, N; Roudaut, M; Townsend, R; Wood, I; Wygant, G | 1 |
| Iqbal, N; Ji, L; Li, H; List, JF; Ma, J; Mansfield, TA; Ptaszynska, A; T'joen, CL | 1 |
| Broedl, UC; Cherney, DZ; Fagan, NM; Johansen, OE; Kaspers, S; Partridge, H; Perkins, BA; Soleymanlou, N; Tschirhart, H; Woerle, HJ; Zinman, B | 1 |
| Fung, A; Kline, I; Mayer, C; Meininger, G; Usiskin, K | 1 |
| Del Prato, S; Durán-García, S; Langkilde, AM; Nauck, MA; Parikh, SJ; Rohwedder, K; Sugg, J | 1 |
| Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ | 1 |
| Tahrani, AA | 1 |
| Huang, YL; Lai, D; Shen, HP; Yang, XP; Zhong, XY | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Dobbins, R; Dorey, DJ; Kler, L; Lorimer, JD; O'Connor-Semmes, R; Sykes, AP; Walker, S; Wilkison, WO | 1 |
| Bogle, A; Chalamandaris, AG; Edelman, S; Griffen, SC; Henry, RR; Iqbal, N; Kasichayanula, S; List, J; Mudaliar, S; Rosenstock, J | 1 |
| Barnett, AH; Jahagirdar, V | 1 |
| Lajara, R | 1 |
| Cook, W; Hansen, L; Hirshberg, B; Iqbal, N; Li, Y; Rosenstock, J; Zee, P | 1 |
| Alba, M; Capuano, G; de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Vercruysse, F; Ways, K | 1 |
| Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 1 |
| Bowering, K; Grohl, A; Matthaei, S; Parikh, S; Rohwedder, K | 1 |
| Rušavý, Z | 1 |
| Kvapil, M | 1 |
| Pelikánová, T | 1 |
| White, JR | 1 |
| Del Prato, S; Durán-Garcia, S; Maffei, L; Nauck, M; Parikh, S; Rohwedder, K; Theuerkauf, A | 1 |
| Araki, E; Broedl, UC; Kim, G; Koiwai, K; Salsali, A; Tanaka, Y; Taniguchi, A; Tanizawa, Y; Woerle, HJ | 1 |
| Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Leiter, LA; Parikh, SJ; Sugg, J | 1 |
| Miller, S; Onge, ES; Whalen, K | 1 |
| Broedl, UC; Christiansen, AV; Häring, HU; Kim, G; Meinicke, T; Merker, L; Roux, F; Salsali, A; Woerle, HJ | 1 |
| Broedl, UC; Jelaska, A; Kim, G; Rosenstock, J; Woerle, HJ; Zeller, C | 1 |
| Broedl, UC; Cescutti, J; Eilbracht, J; Famulla, S; Johansen, OE; Kaspers, S; Pieber, TR; Soleymanlou, N; Woerle, HJ | 1 |
| Broedl, UC; Cui, Y; Lang, B; Macha, S; Pinnetti, S; Salsali, A; Zhao, S; Zhao, X | 1 |
| Bowering, K; Johnsson, E; Matthaei, S; Parikh, S; Rohwedder, K; Sugg, J | 1 |
| Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Li, D; Mathieu, C; Ranetti, AE | 1 |
| Deeks, ED; Kim, ES | 1 |
| Catrinoiu, D; Celiński, A; Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Matthaei, S | 1 |
| Stephens, JW; Williams, DM | 1 |
| Chirila, C; Davenport, E; Hach, T; Kaschinski, D; Palencia, R; Pfarr, E; Zheng, Q | 1 |
| Vivian, E | 1 |
| Fioretto, P; Giaccari, A; Sesti, G | 1 |
| Nakamura, I; Sugamori, H; Terauchi, Y; Yokote, K | 2 |
| Kamaruddin, NA; Kori, N; Mohd Noor, N; Mustafa, N; Othman, H; Rajoo, S; Sukor, N; Wahab, NA; Wan Seman, WJ | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Johnsson, E; Leiter, LA; Parikh, S; Xu, J | 1 |
| Bonnes, H; Katz, A; Skolnik, N; Yeh, H | 1 |
| Davies, MJ; Htike, ZZ; Khunti, K; Webb, DR; Youssef, D; Zaccardi, F | 1 |
| Broedl, UC; Hantel, S; Kaspers, S; Kim, G; Kohler, S; Salsali, A; Woerle, HJ | 1 |
| Levine, MJ | 1 |
| Fioretto, P; Johnsson, E; Mansfield, TA; Parikh, S; Ptaszynska, A; Yavin, Y | 1 |
| Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S | 1 |
| Asahina, S; Ishihara, H; Nakao, I; Okitsu, A; Yamaguchi, S | 1 |
| DeFronzo, RA; Rajeev, SP; Wilding, JP | 1 |
| Carlson, CJ; Santamarina, ML | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U | 1 |
| Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I | 1 |
| Cui, W; Li, D; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
| Mudher Mikhael, E | 1 |
| Dalama, B; Mesa, J | 1 |
| Emoto, N; Hattori, N; Nagamine, T; Nakamura, Y; Okajima, F; Sugihara, H | 1 |
| Broedl, UC; Gallwitz, B; Götz, S; Maldonado-Lutomirsky, M; Nordaby, M; Tinahones, FJ; Woerle, HJ | 1 |
| Abdulsalim, S; Chakraborty, I; Devi, R; Mali, G; Unnikrishnan, MK | 1 |
| Davidson, JA; Sloan, L | 1 |
| Araki, E; Asano, M; Kim, H; Onishi, Y; Yajima, T | 1 |
| Bodegard, J; Eriksson, JW; Nathanson, D; Norhammar, A; Nyström, T; Thuresson, M | 1 |
| Gause-Nilsson, I; Johnsson, E; Kosiborod, M; Sonesson, C; Xu, J | 1 |
| Guo, Y; Li, X; Si, Y; Yang, Y; Zhao, Y; Zhu, H | 1 |
| Pahor, A; Parikh, S; Rohwedder, K; Soler, NG; Sugg, J; Wilding, JP; Woo, V | 1 |
| List, JF; Rosenstock, J; Salsali, A; Vico, M; Wei, L | 1 |
| Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y | 1 |
| Fukazawa, M; Honda, K; Ikeda, S; Kato, M; Kawabe, Y; Kawai, M; Mitsui, T; Murao, N; Nagata, T; Suzuki, Y; Yamaguchi, K; Yamane, M; Yata, T | 1 |
| Saito, A; Seiyaku, T; Tsujihara, K | 1 |
| Deng, RC; Ma, CX; Niu, FL; Zhang, WS; Zhu, LQ | 1 |
| Che, CT; Cheng, CH; Lau, CB; Leung, PS; Li, JM | 1 |
| Ding, F; Gu, X; Liu, M; Yu, S | 1 |
36 review(s) available for glucose, (beta-d)-isomer and Fasting Hypoglycemia
| Article | Year |
|---|---|
A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Network Meta-Analysis | 2022 |
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycogen; Glycogen Storage Disease Type I; Hypoglycemia; Rats | 2023 |
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Dapagliflozin for the treatment of type 1 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hyperuricemia; Hypoglycemia; Hypoglycemic Agents; Membrane Transport Modulators; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Uric Acid | 2018 |
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Topics: Adult; Aged; Amputation, Surgical; Benzhydryl Compounds; Blood Volume; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Double-Blind Method; Female; Fractures, Spontaneous; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections | 2018 |
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain | 2018 |
The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Oral semaglutide for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Sitagliptin Phosphate | 2019 |
New Medications for the Treatment of Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Dapagliflozin: A Review in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Pregnancy; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
Topics: Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2014 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Empagliflozin for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2015 |
Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; United States | 2015 |
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Urinary Tract Infections | 2015 |
Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2015 |
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Topics: B-Cell Activating Factor; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Network Meta-Analysis; Odds Ratio; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2016 |
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2016 |
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.
Topics: Algorithms; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Receptors, Glucagon; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Odds Ratio; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2017 |
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide-1 Receptor; Glucosides; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Peptides; Pyrrolidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Vildagliptin | 2016 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Proteinuria; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Vascular Stiffness | 2016 |
Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
[SGLT inhibitor (T-1095)].
Topics: Animals; Carbonates; Diabetes Mellitus; Disease Models, Animal; Drug Design; Energy Metabolism; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Kidney; Monosaccharide Transport Proteins | 2002 |
55 trial(s) available for glucose, (beta-d)-isomer and Fasting Hypoglycemia
| Article | Year |
|---|---|
SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Glucosides; Glycemic Control; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
Topics: Adolescent; Benzhydryl Compounds; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Prospective Studies; Treatment Outcome; Young Adult | 2022 |
Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Over Studies; Double-Blind Method; Gastric Bypass; Glucosides; Humans; Hypoglycemia; Prospective Studies; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Male; Middle Aged; Prognosis; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2020 |
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2020 |
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with
Topics: Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Equivalence Trials as Topic; Glucocorticoids; Glucosides; Glycemic Control; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Isophane; Monitoring, Physiologic; Multicenter Studies as Topic; Patient Reported Outcome Measures; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2020 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Topics: Activities of Daily Living; Aged; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Japan; Male; Membrane Transport Modulators; Middle Aged; Monitoring, Ambulatory; Risk; ROC Curve; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Asia; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome | 2018 |
Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease.
Topics: Aged; Benzhydryl Compounds; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Glucose; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Length of Stay; Male; Middle Aged; Monitoring, Ambulatory; Prednisone; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Tissue | 2018 |
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Electric Impedance; Glucose Clamp Technique; Glucosides; Glycated Hemoglobin; Hyperglycemia; Hypoglycemia; Insulin Resistance; Overweight; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin; Insulin Resistance; Japan; Male; Middle Aged; Risk; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2018 |
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult | 2018 |
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2018 |
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2018 |
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2019 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2014 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Topics: Adult; Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Hypoglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Membrane Transport Modulators; Middle Aged; Patient Dropouts; Pioglitazone; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss | 2015 |
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2015 |
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Insulin; Male; Middle Aged; Mycoses; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2015 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; United Kingdom; Weight Loss | 2015 |
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Topics: Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Risk Factors; Treatment Outcome; Urinary Tract Infections | 2015 |
Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Exercise; Female; Glucosides; Humans; Hyperglycemia; Hypertension; Hypoglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Overweight; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Detemir; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2015 |
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
Topics: Adult; Austria; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss | 2015 |
Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycosuria; Half-Life; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Fasting; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Young Adult | 2016 |
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Topics: Adiponectin; Aged; Asian People; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Reproductive Tract Infections; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2016 |
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pancreatitis; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2017 |
Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Time Factors; Treatment Outcome | 2017 |
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2012 |
37 other study(ies) available for glucose, (beta-d)-isomer and Fasting Hypoglycemia
| Article | Year |
|---|---|
ATTEMPTS TO TRANSMIT BOVINE ANAPLASMOSIS TO SMALL LABORATORY ANIMALS.
Topics: Adrenalectomy; Allergy and Immunology; Anaplasma; Anaplasmosis; Animals; Animals, Laboratory; Blood; Cats; Cattle; Cattle Diseases; Cortisone; Cricetinae; Guinea Pigs; Hypoglycemia; Mice; Mucins; Pharmacology; Protozoan Infections; Rabbits; Radiation Effects; Rats; Research; Riboflavin Deficiency; Rodentia; Species Specificity; Splenectomy; Zymosan | 1965 |
Stem cell factor-deficient mice have a dysregulation of cytokine production during local inflammation.
Topics: Animals; Ascitic Fluid; Body Weight; Cytokines; Disease Models, Animal; Female; Hypoglycemia; Inflammation; Irritants; Mice; Mice, Mutant Strains; Peritoneal Cavity; Peritonitis; Stem Cell Factor; Turpentine; Weight Loss; Zymosan | 1998 |
The hypoglycemic activity of endotoxin. I. Occurrence in animals hyperreactive to endotoxin.
Topics: Adrenal Glands; Adrenalectomy; Animals; Diabetes Mellitus, Experimental; Endotoxins; Female; Hypoglycemia; Mice; Mycobacterium bovis; Rabbits; Zymosan | 1969 |
Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report.
Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemia; Ketosis | 2022 |
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Prospective Studies; Sitagliptin Phosphate; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2022 |
A new perspective on lowering CV risk from hypoglycaemia.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemia | 2020 |
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Topics: Benzhydryl Compounds; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Middle Aged; Sitagliptin Phosphate; United States; Weight Loss | 2019 |
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
[New Developments in Type 1 Diabetes].
Topics: Benzhydryl Compounds; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glucosides; Humans; Hypoglycemia; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Resistance; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency; Renin-Angiotensin System; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Incidence; Kaplan-Meier Estimate; Male; Membrane Transport Modulators; Middle Aged; Norway; Proportional Hazards Models; Risk; Sodium-Glucose Transporter 2; Sweden | 2018 |
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Health Expenditures; Health Resources; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years; Sulfonylurea Compounds; Thiazolidinediones; United Nations; United States | 2018 |
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus; Female; Glucagon; Glucagon-Secreting Cells; Glucosides; Humans; Hypoglycemia; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Insulin; Receptors, Somatostatin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Somatostatin | 2019 |
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemia; Ketosis; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Synthesis and neuroprotective effects of the fluorine substituted salidroside analogues in the PC12 cell model exposed to hypoglycemia and serum limitation.
Topics: Animals; Apoptosis; Culture Media; Fluorine; Glucosides; Hypoglycemia; Models, Biological; Neuroprotective Agents; PC12 Cells; Phenols; Plant Roots; Rats; Rhodiola | 2013 |
Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Topics: Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney Function Tests; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Severity of Illness Index; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
[New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Quality of Life; Sodium-Glucose Transporter 2; Treatment Outcome | 2014 |
[Empagliflozin: another of silent revolutioners].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 | 2014 |
[Will the new SGLT2 inhibitor empagliflozin help us reduce the risk of hypoglycemia?].
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Quality of Life; Sodium-Glucose Transporter 2; Treatment Outcome | 2014 |
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
Topics: Adult; Benzhydryl Compounds; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Personal Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome | 2016 |
Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Product Surveillance, Postmarketing; Surveys and Questionnaires; Thiophenes | 2016 |
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Renal Insufficiency; Urinary Tract Infections | 2016 |
Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies | 2016 |
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Safety; Urinary Tract Infections | 2016 |
Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Product Surveillance, Postmarketing; Risk Factors; Surveys and Questionnaires; Thiophenes | 2016 |
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome | 2016 |
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Topics: Administration, Oral; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Registries; Risk Factors; Sweden | 2017 |
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diuretics, Osmotic; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Longitudinal Studies; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Sodium-Glucose Transport Proteins | 2017 |
Synthesis and biological evaluation of two salidroside analogues in the PC12 cell model exposed to hypoglycemia and serum limitation.
Topics: Animals; Apoptosis; Glucosides; Hypoglycemia; PC12 Cells; Phenols; Rats; Rhodiola; Serum | 2011 |
Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Topics: Absorption; Animals; Benzhydryl Compounds; Blood Glucose; Creatinine; Dose-Response Relationship, Drug; Gluconeogenesis; Glucosides; Glycosuria; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Phlorhizin; Rats; Rats, Wistar; Sodium Channel Blockers; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
[Protective effects of salidroside on injury induced by hypoxia/hypoglycemia in cultured neurons].
Topics: Apoptosis; Calcium; Cell Hypoxia; Glucosides; Humans; Hypoglycemia; L-Lactate Dehydrogenase; Neurons; Neuroprotective Agents; Phenols; Plants, Medicinal; Rhodiola | 2004 |
Desoxyrhaponticin (3,5-dihydroxy-4'-methoxystilbene 3-O-beta-D-glucoside) inhibits glucose uptake in the intestine and kidney: In vitro and in vivo studies.
Topics: Animals; Biological Transport; Diabetes Mellitus, Experimental; Glucose; Glucosides; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Intestinal Mucosa; Kidney; Microvilli; Rabbits; Rats; Rats, Wistar; Stilbenes | 2007 |
Neuroprotective effects of salidroside in the PC12 cell model exposed to hypoglycemia and serum limitation.
Topics: Animals; Annexin A5; bcl-2-Associated X Protein; Caspase 3; Cell Death; Flow Cytometry; Gene Expression Regulation; Glucosides; Hypoglycemia; Membrane Potential, Mitochondrial; Microscopy, Confocal; Models, Biological; Neuroprotective Agents; PC12 Cells; Phenols; Propidium; Rats; Reactive Oxygen Species; RNA, Messenger; Serum | 2008 |